Research Study

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Principal Investigator 
Heather J. Sutherland

Overview

Disorders and Conditions 
Multiple Myeloma
ClinicalTrials.gov# 
NCT03652064
Status 
Recruiting
Study Start/End 
Feb 15, 2019 to Apr 30, 2025
Locations 
Vancouver General Hospital
Name/Title 
Isabel Taake, Clinical Research Coordinator
Phone 
604-875-4111 ext.22948
Purpose of Study 

The purpose of this study to determine if the addition of daratumumab to bortezomib + lenalidomide + dexamethasone (VRd) will improve overall minimal residual disease (MRD) negativity rate compared with VRd alone.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.